GSK's top dealmaker joins FierceBiotech panel

I'm very pleased to report that we've enlisted the help of Ad Rawcliffe for our upcoming webinar on landing a deal, which is coming up on October 27.

Rawcliffe is one of the most experienced dealmakers in the industry. As senior vice president, worldwide business development and R&D finance for GlaxoSmithKline, Rawcliffe has global responsibility for pharmaceuticals R&D business development activities, including co-development, in-licensing, options based drug discovery collaborations, product acquisition, co-promotion/co-marketing arrangements, and R&D driven M&A activity. 

He'll be joining Anna Protopapas, SVP of Corporate Development & Strategy for Millennium Takeda and Geoff Meyerson and Jay Mohr of Locust Walk Partners to present some clear ideas on how biotech companies can go about striking the best deal possible for their programs and technologies. Meyerson and Mohr will also unveil the results of a new industry survey that will provide some key insights into what pharma companies are looking for and where some of the best new deal-making opportunities lie.  

This is one webinar that can be valuable for your company's future. Go here to sign up. -- John Carroll

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.